TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01612455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINC Case Management
Description: The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
Study: NCT00987493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: day 1 at a fixed dose of 375mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
Study: NCT04109833

Intervention type: DRUG
Intervention: ABT
Description: any antibiotic therapy in the first week of life
Study: NCT03947970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] CR845
Description: Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
Study: NCT01913704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NatroxTM Device
Description: The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NatroxTM Device
Description: The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.
Study: NCT03331783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hydrocolloid adhesive patch
Description: This patch is made of a standard hydrocolloid adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-2
Description: This patch is made of a new adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LT-21
Description: This patch is made of a new adhesive

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 33-20
Description: This patch is made of a new adhesive
Study: NCT00853840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
Study: NCT03016962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cap-assisted colonoscopy
Description: cap-assisted colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy
Study: NCT00441311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Academic Detailing
Description: The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
Study: NCT00853840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
Study: NCT02913391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recruitment group (RG)
Description: After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group (CG)
Description: After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
Study: NCT00853840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
Study: NCT02308254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide
Description: Abdominal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Abdominal administration
Study: NCT03738891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study: NCT01161914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerezyme®
Description: administered by IV infusion for a dose of 60 U/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302
Description: administered by IV infusion for a dose of 60 U/kg
Study: NCT00497172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER Sirolimus-eluting stent
Description: drug-eluting stent
Study: NCT00853840

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
Study: NCT04287686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human angiotensin-converting enzyme 2 (rhACE2)
Description: In this study, the experimental group will receive 0.4 mg/kg rhACE2 IV BID for 7 days.
Study: NCT05647668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic fundoplication
Description: Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic fundoplication
Description: Creation of either a 360° (in Nissen group) or a 270° (in Toupet group) fundoplication wrap over a 30-Fr intra-esophageal bougie.
Study: NCT00497172

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bx SONIC bare metal stent
Description: bare-metal stent
Study: NCT04150276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP during awakening
Description: ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
Study: NCT02184429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06669571
Description: Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
Study: NCT03344198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training exercise & Modified Mediterranean diet
Description: Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training exercise & Modified Mediterranean diet
Description: Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit Training exercise & Modified Mediterranean diet
Description: Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
Study: NCT02008357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solanezumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered IV
Study: NCT04239300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delivery in water
Description: Participants delivery in water
Study: NCT03715192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3462817 IV
Description: Administered IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3462817 SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT03235219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64565111
Description: Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
Study: NCT03262116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog
Description: Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
Study: NCT04162678

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood via HD-SCA fluid biopsy

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04150276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP during awakening
Description: PEEP will be maintained throughout emergence preoxygenation and awakening.
Study: NCT03262116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog
Description: Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC222 insulin lispro
Description: Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: The insulin-only bionic pancreas will be used in all three arms of the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: The insulin-only bionic pancreas will be used in all three arms of the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: The insulin-only bionic pancreas will be used in all three arms of the study
Study: NCT00117793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Surface Bearing Suction Socket
Description: Current clinical practice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum assisted socket system
Description: Novel socket system
Study: NCT01528748

Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy
Description: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
Study: NCT03070197

Intervention type: OTHER
Intervention: Exposure of interest: Brain MRI
Description: Brain MRI will be conducted in all participants

Intervention type: OTHER
Intervention: Exposure of interest: Brain MRI
Description: Brain MRI will be conducted in all participants

Intervention type: OTHER
Intervention: Exposure of interest: neurodevelopmental assessments
Description: neurodevelopmental testing will be conducted in all participants.

Intervention type: OTHER
Intervention: Exposure of interest: neurodevelopmental assessments
Description: neurodevelopmental testing will be conducted in all participants.
Study: NCT00821249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-520, KSP(Eg5) inhibitor; intravenous
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, steroid; oral
Description: Part 3: standard of care.
Study: NCT03864393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal overground locomotor training
Description: Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
Study: NCT02482857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: To compare BID dosing with OD dosing with clinically used aspirin dosages.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: To compare BID dosing with OD dosing with clinically used aspirin dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: To compare BID dosing with OD dosing with clinically used aspirin dosages.
Study: NCT02565810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab PFS and Pen
Study: NCT01608503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung deflation
Description: lung was deflated during respiration cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lung inflation
Description: lung was inflated during respiratory cycle
Study: NCT02776592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow's milk-based formula with added nutrients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk-based formula
Study: NCT03833713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Dialogue
Description: Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS Assessments
Description: Once-weekly SMS assessments of motor vehicle risks
Study: NCT02995551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic meniscal repair or resection
Description: Arthroscopic meniscal repair or resection following standard procedures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and education
Description: A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
Study: NCT04828291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Benign Behavioral Interventions
Description: This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benign Behavioral Interventions
Description: This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benign Behavioral Interventions
Description: This project will use a Randomized Control Trial (RCT) design and Daily Reconstruction Method (DRM8) to model the effects of the OMI on dynamic changes in first-year undergraduate and graduate students' well-being over time. The intervention will take place over the course of 46 days, with a 7- day follow up assessment taking place one month after the intervention. People will complete surveys through an online link leading to Qualtrics.com.
Study: NCT03504566

Intervention type: DRUG
Group type: OTHER
Intervention: Linagliptin
Description: Linagliptin

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: Empagliflozin

Intervention type: DRUG
Group type: OTHER
Intervention: Telmisartan
Description: Telmisartan

Intervention type: DRUG
Group type: OTHER
Intervention: Sulodexide
Description: Sulodexide
Study: NCT04445623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel Hydrochloride 10 MG Oral Tablet
Description: administration of prasugrel daily for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of placebo daily for 15 days
Study: NCT04467970

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Replacement
Description: Unicompartmental Knee Replacement involves replacement of the medial compartment of the knee in patients with anteromedial osteoarthritis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Tibial Osteotomy
Description: High Tibial Osteotomy involves medial wedge opening high tibial osteotomy in cases of anteromedial osteoarthritis.
Study: NCT02170766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 low1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 low2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 medium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 high
Study: NCT02089529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no information, positive information and neutral information
Study: NCT02368652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16mg
Description: Daily oral administration for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg, Candesartan cilexetil 16mg
Description: Daily oral administration for 8 weeks
Study: NCT04162678

Intervention type: PROCEDURE
Intervention: Liquid Biopsy
Description: Undergo collection of blood via HD-SCA fluid biopsy